Zenas BioPharma, Inc.
NASDAQ Global SelectTotal Valuation
Zenas BioPharma, Inc. carries a market capitalization of 1.74B, placing it among publicly traded companies globally. Its enterprise value stands at 1.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.74B |
| Enterprise Value | 1.26B |
Share Statistics
Zenas BioPharma, Inc. currently has 63.33M shares outstanding.
| Shares Outstanding | 63.33M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1,357.17, and the price-to-book ratio stands at 6.50.
| PE Ratio | N/A |
| PS Ratio | 1,357.17 |
| PB Ratio | 6.50 |
| P/TBV Ratio | 6.50 |
| P/FCF Ratio | -7.11 |
| P/OCF Ratio | -6.01 |
Enterprise Valuation
| EV / Sales | 1,262.07 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Zenas BioPharma, Inc. maintains a current ratio of 9.93, meaning it holds 9.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 120.54, indicating elevated leverage, while an interest coverage ratio of -16.17 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.93 |
| Quick Ratio | 9.77 |
| Debt / Equity | 120.54 |
| Debt / EBITDA | -1.09 |
| Interest Coverage | -16.17 |
Financial Efficiency
| Return on Equity (ROE) | -199.04 |
| Return on Assets (ROA) | -97.39 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 220,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Zenas BioPharma, Inc.'s stock has gained approximately 2.14149% over the past 52 weeks. The 50-day moving average sits at 30.04, while the 200-day moving average is 24.59.
| Beta (5Y) | N/A |
| 52-Week Price Change | 2.14149% |
| 50-Day Moving Average | 30.04 |
| 200-Day Moving Average | 24.59 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Zenas BioPharma, Inc. generated 1.00M in revenue and converted that into -484.38M in net income, yielding earnings per share of -9.06. EBITDA reached -273.87M, while operating income came in at -273.90M.
| Revenue | 1.00M |
| Gross Profit | N/A |
| Operating Income | -273.90M |
| Pretax Income | -484.16M |
| Net Income | -484.38M |
| EBITDA | -273.87M |
| EBIT | -273.90M |
| Earnings Per Share (EPS) | -9.06 |
Balance Sheet
Zenas BioPharma, Inc. holds 643.13M in cash and equivalents against 297.86M in total debt, resulting in a net debt position of 100.44M. Total book value stands at 247.10M, with working capital of 587.98M providing operational flexibility.
| Cash & Cash Equivalents | 643.13M |
| Total Debt | 297.86M |
| Net Debt | 100.44M |
| Equity (Book Value) | 247.10M |
| Book Value Per Share | 3.90 |
| Working Capital | 587.98M |
Cash Flow
Zenas BioPharma, Inc. produced -225.97M in operating cash flow over the past twelve months. After subtracting -35.00M in capital expenditures, free cash flow totaled -260.97M - equivalent to -4.88 per share.
| Operating Cash Flow | -225.97M |
| Capital Expenditures | -35.00M |
| Free Cash Flow | -260.97M |
| FCF Per Share | -4.88 |
Margins
Zenas BioPharma, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -27,390.10 and net profit margin of -48,438.40 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -27,390.10 |
| Pretax Margin | -48,416.40 |
| Profit Margin | -48,438.40 |
| EBITDA Margin | -27,387.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -42.87 |
| FCF Yield | -14.07 |
Scores
Zenas BioPharma, Inc. posts an Altman Z-Score of -0.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.07 |